Synonym
JB-11 isethionate; NSC 328564; NSC-328564; NSC328564;
IUPAC/Chemical Name
5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)quinazoline-2,4-diamine 2-hydroxyethane-1-sulfonate
InChi Key
YATKEMOVGUXIDY-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H23N5O3.C2H6O4S/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3;3-1-2-7(4,5)6/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24);3H,1-2H2,(H,4,5,6)
SMILES Code
OCCS(=O)(O)=O.NC1=NC(N)=C2C(C)=C(CNC3=CC(OC)=C(OC)C(OC)=C3)C=CC2=N1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
495.55
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Smith D, Gazzard B. Treatment and prophylaxis of Pneumocystis carinii pneumonia in AIDS patients. Drugs. 1991 Oct;42(4):628-39. Review. PubMed PMID: 1723365.
2: Hughes WT. Prevention and treatment of Pneumocystis carinii pneumonia. Annu Rev Med. 1991;42:287-95. Review. PubMed PMID: 2035974.
3: Wordell CJ, Hauptman SP. Treatment of Pneumocystis carinii pneumonia in patients with AIDS. Clin Pharm. 1988 Jul;7(7):514-27. PubMed PMID: 3138063.
4: Masur H, Kovacs JA. Treatment and prophylaxis of Pneumocystis carinii pneumonia. Infect Dis Clin North Am. 1988 Jun;2(2):419-28. Review. PubMed PMID: 3060526.
5: Allegra CJ, Chabner BA, Tuazon CU, Ogata-Arakaki D, Baird B, Drake JC, Masur H. Treatment of Pneumocystis carinii pneumonia with trimetrexate in acquired immunodeficiency syndrome (AIDS). Semin Oncol. 1988 Apr;15(2 Suppl 2):46-9. PubMed PMID: 2966985.
6: Hughes WT. Treatment and prophylaxis for Pneumocystis carinii pneumonia. Parasitol Today. 1987 Nov;3(11):332-5. PubMed PMID: 15462879.
7: Allegra CJ, Chabner BA, Tuazon CU, Ogata-Arakaki D, Baird B, Drake JC, Simmons JT, Lack EE, Shelhamer JH, Balis F, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1987 Oct 15;317(16):978-85. PubMed PMID: 2958710.
8: Queener SF, Bartlett MS, Jay MA, Durkin MM, Smith JW. Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection. Antimicrob Agents Chemother. 1987 Sep;31(9):1323-7. PubMed PMID: 2445281; PubMed Central PMCID: PMC174935.
